| Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
robin_robinson [2023/10/17 20:32]
pamela [Esperovax Appoints Dr. Robin Robinson as President and CEO] | robin_robinson [2023/10/17 20:41] (current)
pamela [COVID mRNA Contract Awards] |
|---|
| See Global Virome Project - Ecohealth Alliance and Dr. [[:Dennis Carroll]] Director of the U.S. Agency for International Development's (USAID's) Pandemic Influenza and other Emerging Threats Unit. In this position, he led [[:USAID]]'s Emerging Pandemic Threats program, a global effort to combat new disease threats before they can become significant threats to human health. Dennis was responsible for providing strategic and operational leadership for the agency's programs addressing new and emerging disease threats, which has included leading the agency's response to the [[:H5N1]] **avian influenza and H1N1 pandemic** viral threats. ((https://www.campfire.wiki/doku.php?id=global_virome_project&s[]=h5n1)) | See Global Virome Project - Ecohealth Alliance and Dr. [[:Dennis Carroll]] Director of the U.S. Agency for International Development's (USAID's) Pandemic Influenza and other Emerging Threats Unit. In this position, he led [[:USAID]]'s Emerging Pandemic Threats program, a global effort to combat new disease threats before they can become significant threats to human health. Dennis was responsible for providing strategic and operational leadership for the agency's programs addressing new and emerging disease threats, which has included leading the agency's response to the [[:H5N1]] **avian influenza and H1N1 pandemic** viral threats. ((https://www.campfire.wiki/doku.php?id=global_virome_project&s[]=h5n1)) |
| |
| | ==== COVID mRNA Contract Awards ==== |
| | {{ ::esperovax_robin_robinson_2023_contract_mrna_covid.png?400|}} |
| | PLYMOUTH, Mich., Oct. 3, 2023 /PRNewswire/ -- [[:Esperovax]], a U.S.-based preclinical biopharmaceutical company and a [[:BLUE KNIGHT]]™ resident company, is receiving an award for $ 1 M to further develop a **yeast-based oral COVID-19 RNA vaccine** candidate as part of the BLUE KNIGHT™ QuickFire Challenge: Accelerating [[:Project NextGen]]. |
| | |
| | This award will support critical studies aimed at demonstrating vaccine safety and immunoprotection in **orally vaccinated animals** challenged with different [[:COVID-19]] virus variants. Esperovax is collaborating with Dr. [[:Slobodan Paessler]] at the [[:University of Texas]] Medical Branch – Galveston to conduct these studies. |
| | |
| | Blue Knight, a joint initiative between [[:Johnson & Johnson]] Innovation – JLABS (JLABS) and the [[:Biomedical Advanced Research and Development Authority]] (BARDA), collaborates with companies to accelerate innovation against emerging health security threats. |
| | |
| | "This award enables animal challenge studies that may determine whether our unique oral COVID-19 [[:RNA vaccine]] elicits protective immunity that prevents disease and reduces virus dissemination and affords completion of other requisite studies supportive of an Investigational New Drug application for future clinical evaluation," stated Dr. Robin Robinson, President and Chief Executive Officer. "Positive results from these studies have the potential to bring inexpensive, safe and long-lasting effective oral vaccines a step closer to address public health threats like COVID-19 and other emerging infectious diseases." |
| | |
| | About Esperovax: Esperovax was founded in 2019 to advance development of its Egress RD™ oral [[:mRNA]] platform, a transformative technology for delivering [[:mRNA vaccines]] to the abundant populations of immune cells in the gastrointestinal tract via a small oral capsule. |
| | |
| | For more information, please visit our web site at www.esperovax.com((https://web.archive.org/web/20231009024444/https://www.prnewswire.com/news-releases/esperovax-awarded-1m-for-development-of-an-oral-covid-19-rna-vaccine-under-the-hhs-project-nextgen-initiative-301945741.html)) |
